{"name":"Caliway Biopharmaceuticals Co., Ltd.","slug":"caliway-biopharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"caliwaybiopharmaceuticals.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CBL-A1 Injection","genericName":"CBL-A1 Injection","slug":"cbl-a1-injection","indication":"Other","status":"phase_2"},{"name":"CBL-A2 Injection","genericName":"CBL-A2 Injection","slug":"cbl-a2-injection","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CBL-514","genericName":"CBL-514","slug":"cbl-514","indication":"FGFR-driven solid tumors (specific indications in phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"CBL-A1 Injection","genericName":"CBL-A1 Injection","slug":"cbl-a1-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CBL-514","genericName":"CBL-514","slug":"cbl-514","phase":"phase_3","mechanism":"CBL-514 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling.","indications":["FGFR-driven solid tumors (specific indications in phase 3 development)"],"catalyst":""},{"name":"CBL-A2 Injection","genericName":"CBL-A2 Injection","slug":"cbl-a2-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOQS15X0h6WXBMa3duQ1RmWE9tSFJEdFFMUmR5Z2s0aDVrVkhPWlFJQ0RjZVEyTUh5dzlWdHlMbWdHMW1UVS1XOWplZ0Etd1lVQkhITWJEVlNubmNhUXRaTUtmQmhnekRyZUl2ZW9GUUdtSUd1SGFHRVltRnVxQmI0MGpwNkdfVnJhU25VNFRwSlBVZFU1V2lYZ3drUlZQX29NdkQxbWdKUWNZS3RJTzE0VjBKb01VVklIQWZDOUtKX0p5WGR5Vy1BRi1uRFBPWDB5aW0xZnNTb2N5d2JvRUVmbVJNa2Vva0ozSm9wX194MkE3LVpydTJrbdIB_gFBVV95cUxOZ0xycFlTY19Qc3BEN1g5ZFFRZkE1ekNCbEtpZjBLVXBYYUNFMkh2cDNpeHBMSWZaaXZsM1RJZUt0Y1VJZlc1YlBMWFRPMXhPS3E5TzU4bWZRQkZlQXd4VGJiOURBdE5RZ283Q2JhbnBQN3hxWWlhNHhvbnZrMXFHdkxJX1FSWnBnMHU5cTZtMC1ZREhEY0pzX181X3ZmTEFJOEdQTm13LXRSc2owN3k0YW1rbTBEWnBDQzdPaGZmUmNPQTZRbHN4aEJrWGFkc1BPdWZUN1JnOUg5Z1lQZExIM2l6a0o0RXlWQTBoSUNpa2xadXNxZ3otZlFIMXlSZw?oc=5","date":"2025-09-09","type":"pipeline","source":"simplywall.st","summary":"Caliway Biopharmaceuticals (TWSE:6919): Assessing Valuation After a Significant Share Price Rally - simplywall.st","headline":"Caliway Biopharmaceuticals (TWSE:6919): Assessing Valuation After a Significant Share Price Rally","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxNRzNnMFJIUWdiUDl1Y3B0VVJTWnJlVWRGZ0pBblFYQnlYZWVUN2lfUlA5SVR4UWdZY1VRUklOUUwyWmRUc2hQNzk2UU9CZWlaZndpenFESkNMTTkyOVNILU1wQVFWRGxUMklUX0tnT3gwUnk2N1RZd1YxbTBkLXpCbjYzX1ZuN0N2N2tZNmk0UWloVWJvYU1oSldxZjNFYkNjZ3loTlUteGZvaUZlZ3dLV185dHNhUm5FLVIzal9CLXp0N2ZJQlVWcktMUWh6dkNRalFzWWszWmZxWmdQTXVjbm1kLWVYc3V3OFBXZWRZX2tMR1F6amd2cVBONjlPaG5aY2Jfd0stY3ZKQmt1Uy1MUER0NlBOWGYxZ3luTnNTa3RBRlhyb3NJMDZFc3RRb3ptQXlTaTF6cTlUeXc5T1d0N1dPWjVHeEU?oc=5","date":"2025-07-28","type":"regulatory","source":"PR Newswire","summary":"Caliway Announces FDA Clearance of IND Application for CBL-514 to Proceed with SUPREME-01, the First Global Pivotal Phase 3 Study for Reducing Abdominal Subcutaneous Fat - PR Newswire","headline":"Caliway Announces FDA Clearance of IND Application for CBL-514 to Proceed with SUPREME-01, the First Global Pivotal Phas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBPdHhZU0NYUTBSN1huR2RFbE0tcVRaWWs0NHpyZm1DaGtYQTlZd3dHLW1NcVliVVlpWlF3UEtIM1lIUGF6REdWQzJNRzhFZW5QbWVQNnE4azY4WS1KbDJUbExFN3pmN3pPZEJzTTlnWmE?oc=5","date":"2025-03-05","type":"pipeline","source":"Labiotech.eu","summary":"The 7 hottest biotech companies in Taiwan - Labiotech.eu","headline":"The 7 hottest biotech companies in Taiwan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNdE0wbHVFRHdNT0ljb3FDVDI4SFNncjk5Q3I3TnZOQnBiNm5kNVpNZXBEbmN5bmNTSW1GOVlrcDhBWVY4bFdHTUd5NkVnMGUxMmlxR2M4LVgwVkFsUmVPSThrdFNWMXU3cW5IcDQxLUlsZXYzRU9CZDY1cmpJUlZ4eWhXdDNueEFQV3ZwQnV1RHdsbzlvVS1HMkxpMmpVU1BuVGEyZHFldmtlSC01MUxERkRxVlI5d1VVWTRXUVloandjRXFfX1JCcA?oc=5","date":"2025-03-01","type":"pipeline","source":"BioSpectrum Asia","summary":"“Biotech sector in Taiwan moves fast, making it easier to pivot and innovate†- BioSpectrum Asia","headline":"“Biotech sector in Taiwan moves fast, making it easier to pivot and innovateâ€","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxONTVRLUZHbllLSlVIUmN4bUhCb2ViUWZucmdYVVdjVzd2MnVFU2FjRC0tQkJEWjAzek1fdk40dlMyQnhDQzU3WXBSNmpaN2RHbW8wSGNHTGFPRE81c0xtVGdxaXBGU1NnYU1zeGVPRVR3Y1dja1doVUdJbHkwRkpWWGVRc0oyX1YxeEJMMmFtRjVXWE45OFhtdDZDMmY4SkdjNm5pRkZQdmtXSFR2MFdsRXp6REVodE92aklDSExfZ0JvbVBVSFBBX1c2bFM2REhJcVI4T2U3Y1VhaXBtZGphTWNxNWRPQzgzWkJVYlpR?oc=5","date":"2024-12-19","type":"pipeline","source":"PR Newswire","summary":"Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices - PR Newswire","headline":"Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPZXg2Yi1qUUdLVm56QUlQaG9DRTVwNkU3Z3RQaDk3Z29IVkJGOVB2Y0h6OUk2OVNTT3FzMklmTDluSnktVl81VUZ2UHR5MFFUdjVNanRyMnZQS1JsTVZnUi1UYkFYN1FYSGhFZ2FxS0I0aG1mY0ZIYXc4RUtDM0VWa0dSM3AzeWJsbGpQRjNGV1VEd2RCZ2daSHlVeXVGT0tseUpPNUI0YVlIOVhjaVZSNDN2NzA4aGlKaEc3VDlIZW1RbWZqdkd0dU56a2t0LW9sR2pXMzBDQTU5dXFxMVZ2Y01ZaWFtS2ZaY1ltRzg5Qkt4UkEyT2h3ZkFn?oc=5","date":"2024-10-24","type":"trial","source":"BioPharma APAC","summary":"Taiwan’s Caliway Biopharmaceuticals Completes Final Phase 2b Study of CBL-514, First Injectable for Large-Area Fat Reduction - BioPharma APAC","headline":"Taiwan’s Caliway Biopharmaceuticals Completes Final Phase 2b Study of CBL-514, First Injectable for Large-Area Fat Reduc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFB1WDU5ck55RW43elc4OXg0VlpSNHlWcEI5NVFYamJwSlJGbzFZZk1HaVhDcl9TbTB6RjE5S3BPVEFRNUdYZERVcVZMRHZYdmtQcHlEZXh3?oc=5","date":"2024-10-06","type":"pipeline","source":"Yahoo Finance UK","summary":"CALIWAY BIOPHARMACEUTICALS CO L (6919.TW) stock price, news, quote and history - Yahoo Finance UK","headline":"CALIWAY BIOPHARMACEUTICALS CO L (6919.TW) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE04bC1UWVpqUUg5dE5WeGRNLUVoVi0zbHg4bU5jak5IZEg3VXhFbXVmV2NxSmNpZ0drN2syNURnWi1OWFI2aVZlQkhVMUpPRGFXSjlxTmp6UUxDQQ?oc=5","date":"2024-10-01","type":"pipeline","source":"TradingView","summary":"6919 Stock Price and Chart — TWSE:6919 - TradingView","headline":"6919 Stock Price and Chart — TWSE:6919","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"GlobeNewswire","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - GlobeNewswire","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPRXFSWFBBWmlHOEpmc1hLQ3lBQ25RQkVyMEYtNy16XzVzU2NJUlR5QmNjQXNsU3h2MUZlVVRjLUdsaW11Z0dvbUs2azJZV1ZXZHJfa1h6bU84MkJpUFd3OGFLQzJrY0VKbE4wODBXbWExeWYyOTZGQjAyWGFHSmF5YzhaRWg1ZXZHTlYzZTJNTnljMi1qTmd6MVRyNXR4eUhZZ1dyREt0SnNwVlV4UlM5R2VSaDZsd1RXQlY4d3dfR3pJdVE?oc=5","date":"2024-03-05","type":"regulatory","source":"Pharmacy Times","summary":"FDA Grants Orphan Drug Designation for CBL-514 to Treat Adult Patients With Dercum Disease - Pharmacy Times","headline":"FDA Grants Orphan Drug Designation for CBL-514 to Treat Adult Patients With Dercum Disease","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}